Biologics, Inc. has been selected by Exelixis, Inc. to be a specialty pharmacy provider in the limited distribution network for CABOMETYXTM (cabozantinib) tablets.
Approved by the U.S. Food and Drug Administration (FDA) on April 25, 2016, CABOMETYX is indicated for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.
RCC is the seventh most common cancer in men and the ninth most common in women. An estimated 65,000 new cases are diagnosed each year in the United Statesi.
CABOMETYX is a kinase inhibitor that targets multiple tyrosine kinases involved in the development of RCC, including MET, AXL and three VEGF receptors. The approval of CABOMETYX is based on results of the pivotal phase 3 METEOR trial, which met its primary endpoint of improving progression-free survival (PFS) with a median PFS of 7.4 months. The drug received Breakthrough Therapy and Fast Track designation from the FDAii.
“We are excited to be able to support another treatment option for RCC patients,” said Shayne Malone, vice president, Biopharma Services, Biologics, Inc. “Our clinical care team’s high-touch approach to patient care will allow us to support CABOMETYX patients throughout their treatment journey.”
CABOMETYX is the tablet formulation of cabozantinib. Cabozantinib is also approved in a capsule formulation under the brand name of COMETRIQ® for the treatment of progressive, metastatic medullary thyroid cancer.
Biologics’ oncology specialty pharmacy is supported by a multidisciplinary care team that includes a financial counselor, pharmacist and oncology nurse. Individualized care plans are developed to address the clinical, financial and emotional needs of each patient and to streamline communication back to the treating provider.
Physicians may submit prescriptions to Biologics via phone (800.850.4306), fax (800.823.4506) or eScribe. For electronic prescribing systems, physicians may search for Biologics within their EMR system.
Biologics, Inc. is an oncology pharmacy services company that empowers healthcare providers, payers and biopharma to optimize cancer care for the best possible outcomes – clinical, financial and emotional. Unifying fragmented healthcare services, Biologics brings efficiency and humanity to oncology care management by focusing on the patient’s best interest as the surest path to managing cost and risk.
Biologics is part of McKesson Specialty Health, a division of McKesson Corporation empowering the community patient care delivery system by helping community practices advance the science, technology and quality of care. Through innovative clinical research, business and operational solutions, facilitated by integrated technology systems, we focus on improving the financial health of our customers so they may provide the best care to their patients. Our combined organization will help better support patients and expedite access to oncology therapies. For more information, visit www.mckessonspecialtyhealth.com and www.biologicsinc.com.
i “Renal Cell Carcinoma,” Cleveland Clinic, August 2013.
ii “Exelixis Announces FDA Approval of CABOMETYX™ (Cabozantinib) Tablets for Patients with Advanced Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy,” Business Wire, April 25, 2016.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161005005278/en/Business Wire
Last updated on: 05/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.